ArticleJournal of the American Heart Association2024
Global, Regional, and National Burden of Valvular Heart Disease, 1990 to 2021.
Article in Journal of the American Heart Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Unimodal to multimodal: a systematic review of predictive machine learning models for valvular heart diseases.Frontiers in cardiovascular medicine · 2026Pooled it
- Comparing porcine versus bovine mitral valve replacement in terms of structural valve deterioration: a systematic review.Journal of cardiothoracic surgery · 2025Pooled it
- Procedural Sequence in Simultaneous TAVR and PBMV: A 3-Patient Case Series.JACC. Case reports · 2026Article
- Acute rheumatic fever and rheumatic heart disease in Latin America: a contemporary review of epidemiology.Lancet regional health. Americas · 2026Review
- The Epidemiology of Pulmonary Hypertension in Sub-Saharan Africa-A Systematic Report.Pulmonary circulation · 2026Article
- Kickstarting the First Coronary Artery Bypass Graft Program in Papua New Guinea-History Made, Yet a Long Journey Ahead.Journal of clinical medicine · 2026Article
- Early Outcomes of Real-World Aortic Valve Replacement With RESILIA Tissue in the Chinese Population.Clinical cardiology · 2026Article
- Artificial intelligence-enabled electrocardiography to triage echocardiography for structural heart disease diagnosis in a low-resource setting.American journal of preventive cardiology · 2026Article
- A Soft Robotic Model for Simulating Heart Valve Disease and Cardiac Interventions.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Large Animal Models for Preclinical Evaluation of Heart Valve Prostheses, Left Ventricular Assist Devices and Total Artificial Hearts: A Narrative Review.Biomimetics (Basel, Switzerland) · 2026Review
- Automated Classification of Mitral and Tricuspid Regurgitation With Explainability and Real-World Practice Experience.Journal of the American Heart Association · 2026Article
- Advancements and Challenges in Tissue-Engineered Heart Valves: Integrating Biomechanics, Biomaterials, and Biomimetic Design for Functional Maturity.Biomimetics (Basel, Switzerland) · 2026Review
- Clinical outcomes and management strategies for moderate aortic regurgitation in patients undergoing rheumatic mitral valve surgery.Scientific reports · 2026Observational
- Preprocedural Left Atrial Strain as a Predictor of Long-Term Outcomes Following Mitral Valve Interventions in Rheumatic Severe Mitral Stenosis.Journal of the American Heart Association · 2026Observational
- Prognostic value of the AIP index in patients with severe aortic stenosis undergoing transcatheter aortic valve replacement.Frontiers in nutrition · 2026Article
- Clinical and Echocardiographic Factors of Complications in Patients With Mitral Stenosis.Cureus · 2026Article
- Active endothelial and neural regulation of valve biology, health, and disease.Frontiers in cardiovascular medicine · 2026Review
- Income, Geography, and Etiology as Factors Associated with Valve Replacement Outcomes: A Nationwide Cohort of 63,426 Patients in a Middle-Income Country.Global heart · 2026Article
- The association between time-weighted cumulative life's essential 8 and aortic valve calcification.Frontiers in cardiovascular medicine · 2026Article
- From Last Resort to Standard of Care: The Evolution and Future of Transcatheter Aortic Valve Implantation.Reviews in cardiovascular medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundValvular heart disease poses an escalating global health challenge with an increasing impact on mortality and disability. This study aims to comprehensively analyze the global burden of valvular heart disease. METHODS AND
resultsUsing the Global Burden of Disease 2021 data, we analyzed the prevalence and disability-adjusted life years, examining implications across demographics and geographic regions. In 2021, an estimated 54.8 million (95% uncertainty interval [UI], 43.3-67.6) cases of rheumatic heart disease, 13.3 million (95% UI, 11.4-15.2) cases of nonrheumatic calcific aortic valve disease (CAVD), and 15.5 million (95% UI, 14.5-16.7) cases of nonrheumatic degenerative mitral valve disease (DMVD) were reported globally. Despite the rising prevalence, disability-adjusted life years declined between 1991 and 2021. Among individuals aged 70 years or older, the age-standardized prevalences were 1803.6 per 100 000 (95% UI, 1535.5-2055.7) for CAVD and 2148.9 per 100 000 (95% UI, 2001.4-2310.1) for DMVD. Sub-Saharan Africa had the highest age-standardized prevalence for rheumatic heart disease; Conversely, high-income regions led in CAVD and DMVD prevalence. Rheumatic heart disease had the highest age-standardized prevalence of 1184.2 per 100 000 (95% UI, 932.4-1478.2) in low Socio-Demographic Index (SDI) regions, whereas CAVD peaked at 349.8 per 100 000 (95% UI, 303.6-395.8) in high SDI regions. The most substantial increases in age-standardized prevalences of CAVD from 1990 to 2021 occurred in the middle SDI and low-middle SDI regions. A parallel trend was noted for DMVD.
conclusionsRheumatic heart disease remains a significant burden in low SDI regions, whereas CAVD and DMVD pose challenges in high SDI regions with aging populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.